E3S Web of Conferences (Jan 2023)

Green synthesis for the treatment of type-II diabetes

  • Pavani Krishna Kumara Karitla,
  • Kaur Gurmeet

DOI
https://doi.org/10.1051/e3sconf/202343001279
Journal volume & issue
Vol. 430
p. 01279

Abstract

Read online

Type-II diabetes mellitus (T2DM) is a serious threat to human life as till the year 2019, approximately 463 million individuals of age between 20-79 years are suffering with diabetes and it will rise to 700 million by the year 2045. For the testing and diagnosis of diabetes, The WHO and the ADA are using various clinical and laboratory characteristics. Diabetes is a silent killer which cannot be cured, however by changing the lifestyle, losing fat, using low blood sugar medications, and using metformin (biguanide) which helps in reducing insulin resistance, one can control diabetes to an extent. Metformin is widely used medicine to treat obesity. Various short- and long-term problems including premature death occurs in type-II diabetic patients. Due to the late diagnosis and poor medical facilities for type-II diabetes in countries like Africa, they are susceptible to developing diseases that lead to death. This article mainly discusses type-II diabetes mellitus (T2DM) and the drugs used for its cure. It also gives a green synthesis of one of the diabetes drug done in our lab.